Vaxcyte, Inc.
PCVX
Positions held
Your positionsPCVX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Vaxcyte, Inc. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, positioning the company for future growth.
- The company's current market cap stands at approximately $9.93 billion, indicating strong investor interest and confidence in its long-term prospects.
- Vaxcyte has a strong buy recommendation with a score of 62.00, reflecting positive technical indicators such as a rising RSI and MACD.
- Vaxcyte has reported zero revenue for multiple consecutive quarters, which raises concerns about its ability to generate income and sustain operations.
- The company has a significant negative net income of -284.302 million for Q2 2026, highlighting ongoing financial challenges.
- Vaxcyte's debt-to-equity ratio is 4.186, suggesting a high level of debt relative to equity, which could pose risks to financial stability.
Fundamentals
| Market cap | $9.67B | Enterprise value | $8.30B | Trailing P/E | — | Forward P/E | -9.04 |
| PEG | — | Price / book | 3.41 | Beta | 1.23 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -36.5% | ROA | -22.6% | Debt / equity | 0.04 |
| Current ratio | 5.72 | Free cash flow | -$485.76M | Analyst recommendation | strong_buy | Mean target | $117.00 |
| 52w high | $90.75 | 52w low | $39.87 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$284M | -$321M | -$247M | -$213M | -$167M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$303M | -$346M | -$274M | -$242M | -$226M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$767M | -$464M | -$402M | -$223M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$924M | -$570M | -$393M | -$209M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Why Vaxcyte (PCVX) Is Getting Attention Again
2026-10-07 · Vaxcyte Prices $1 Billion Offerings of Stock, Prefunded Warrants, 2032 Notes
2026-10-06 · Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
2026-10-06 · As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
2026-10-06 · Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
2026-10-06 · Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
2026-10-06 · Pfizer’s $6.49 Billion Prevnar Franchise Faces a New Challenger
2026-10-06 · Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
2026-10-05 · NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
2026-10-05 · Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge
2026-10-05 · Vaxcyte stock falls on $1B dual offering launch
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker